hCTLA-4(BALB/c)

品系全名

BALB/cAnSmoc-Ctla4tm1(hCTLA4) Smoc

目录号

NM-HU-190078

品系状态

活体

导出PDF

基因信息

基因名
CTLA4

品系描述

通过NM-HU-00014,hCTLA-4品系回交获得。
应用领域:免疫治疗,肿瘤研究,药物筛选

验证数据

ctla4.png

图1. FACS 检测刀豆蛋白刺激后BALB/c背景 CTLA4人源化纯合子小鼠脾脏淋巴细胞人源CTLA4表达。

图表 1.png

图表 3.png


图2 (A) BALB/c-hCTLA4纯合小鼠中抗人CTLA4抗体抑制CT26肿瘤生长。将小鼠结肠癌细胞CT26移植到BALB/c-hCTLA4纯合小鼠皮下,待肿瘤体积约100mm3时将动物入组至对照组、ipilimumab (Yerovy)治疗组、 entinostat(ENT)治疗组和Yerovy+ENT联用组(n=7)。(B)小鼠体重变化。

结果显示: Yerovy可有效控制 BALB/c-hCTLA4小鼠中的肿瘤生长,ENT可增强这种治疗效果,证明BALB/c-hCTLA4小鼠为抗人 CTLA4 抗体的体内评价提供了有力的临床前模型。

fig4-1.png

fig4-2.png

Fig3. (A) BALB/c-hCTLA4 纯合小鼠中抗人 CTLA4 抗体抑制 H22 肿瘤生长。将小鼠肝癌细胞 H22 移植到 BALB/c-hCTLA4 纯合小鼠皮下,待肿瘤体积约100mm3 时将动物入组至对照组、ipilimumab  (Yerovy) 治疗组、Teremelimumab 治疗组 (n=7)。(B) 小鼠体重变化。

结果显示: Yerovy 和 Teremelimumab 可有效控制 BALB/c-hCTLA4 小鼠中的肿瘤生长,证明BALB/c-hCTLA4 小鼠为抗人 CTLA4 抗体的体内评价提供了有力的临床前模型。


你也可能感兴趣

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

查看
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

查看